Skip to main content
. 2019 Apr 25;9:6569. doi: 10.1038/s41598-019-42982-5

Table 6.

Comparisons of Clinical Characteristics Among Optical Coherence Tomography Angiography-Determined Arteriovenous Crossing Patterns in Eyes with Branch Retinal Vein Occlusion.

Arterial overcrossing (32 eyes) Venous overcrossing (23 eyes) P value
Baseline examinations
      LogMAR visual acuity 0.34 ± 0.23 0.24 ± 0.29 0.158
      Foveal thickness (μm) 516.3 ± 157.9 498.4 ± 146.8 0.380
      Total NPA (disc area) 7.06 ± 12.1 21.5 ± 18.6 0.002
      Total NPA (disc area, only major BRVO) 14.8 ± 15.6 (12 eyes) 26.9 ± 17.5 (19 eyes) 0.064
      Macular NPA in SCP (mm2) 1.50 ± 0.42 1.60 ± 0.73 0.656
      Macular NPA in DCP (mm2) 1.75 ± 0.53 1.75 ± 0.88 0.991
12-months after initial treatment
      LogMAR visual acuity 0.05 ± 0.14 0.02 ± 0.18 0.607
      Total NPA (disc area) 16.7 ± 25.6 44.8 ± 29.2 0.002
      Total NPA (disc area, only major BRVO) 34.7 ± 27.8 (12 eyes) 55.3 ± 22.1 (19 eyes) 0.047
      Central macular NPA in SCP (mm2) 1.41 ± 0.47 1.71 ± 0.61 0.110
      Central macular NPA in DCP (mm2) 1.59 ± 0.56 1.94 ± 0.69 0.090
24-months after initial treatment
      LogMAR visual acuity 0.05 ± 0.13 0.01 ± 0.21 0.469
      Central macular NPA in SCP (mm2) 1.36 ± 0.41 1.59 ± 0.64 0.197
      Central macular NPA in DCP (mm2) 1.67 ± 0.42 1.81 ± 0.66 0.449
      Number of IVR for 24-months 5.6 ± 2.3 4.9 ± 2.4 0.269
      Occurrence of neovascular changes 0 (0%) 6 (31.6%) 0.030

Data are mean ± standard deviation unless otherwise indicated; The analyses of total NPA, neovascular complications were examined after exclusion of eyes with macular branch retinal vein occlusion; logMAR = logarithm of the minimum angle of resolution; NPA = retinal nonperfusion area. SCP = superficial capillary plexus; DCP = deep capillary plexus; IVR = intravitreal ranibizumab injections; Total NPAs were separately indicated in all patients, and in patients with major BRVO; The baseline measurements of optical coherence tomography angiography were obtained after the initial resolution of macular edema and macular hemorrhage.